Survey: Oncologists Show Support For Erbitux Uptake Based On KRAS Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Approach could encourage front-line Erbitux use in some colorectal patients, Rodman & Renshaw finds after oncologist survey.
You may also be interested in...
Leaner Genmab A More Likely Buy For GSK?
Staff cutbacks, dropped programs, and out-licensing plans unveiled.
Leaner Genmab A More Likely Buy For GSK?
Staff cutbacks, dropped programs, and out-licensing plans unveiled.
Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.